報價延遲最少15分鐘:2025/07/06 13:08 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
36.99 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.05/--
|
|
企業價值
1.59B
|
| 資產負債 |
|
每股賬面淨值
0.39
|
| 現金流量 |
|
現金流量率
0.00
|
| 損益表 |
|
收益
8.19M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/06 13:08 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions. |